OBJECTIVES: Recently, aberrations in the gene encoding for ataxia-telangiectasia-mutated (ATM) protein kinase have been reported for pancreatic ductal adenocarcinomas (PDAC). These findings argue that ATM deficiency may play a role during carcinogenesis. Therefore, in this study, we investigated the clinical relevance of ATM expression and ATM activation in PDAC. METHODS: Both ATM expression and nuclear phosphoSer1981-ATM levels were assessed by immunohistochemistry in a cohort of 133 PDAC and correlated with clinicopathological parameters. RESULTS: We found stratification in prognostic subgroups. Complete loss of Ser1981-ATM was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001). Similarly, analysis of ATM expression demonstrated absent expression levels of ATM to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM in general was associated with increased survival (17.7 months, P = 0.001). CONCLUSIONS: Our analysis shows that both ATM expression and activated ATM are prognostic markers in PDAC with respect to standard clinicopathological parameters. These results suggest that ATM should be further explored as prognostic as well as predictive factor with respect to conventional chemotherapies and for putative synthetic lethal approaches.
OBJECTIVES: Recently, aberrations in the gene encoding for ataxia-telangiectasia-mutated (ATM) protein kinase have been reported for pancreatic ductal adenocarcinomas (PDAC). These findings argue that ATM deficiency may play a role during carcinogenesis. Therefore, in this study, we investigated the clinical relevance of ATM expression and ATM activation in PDAC. METHODS: Both ATM expression and nuclear phosphoSer1981-ATM levels were assessed by immunohistochemistry in a cohort of 133 PDAC and correlated with clinicopathological parameters. RESULTS: We found stratification in prognostic subgroups. Complete loss of Ser1981-ATM was indicative of the worst prognosis (median survival, 10.8 vs 14.3 months [low expression] vs 31.1 months [high expression], P < 0.001). Similarly, analysis of ATM expression demonstrated absent expression levels of ATM to be associated with dismal prognosis (median survival, 9.6 months), whereas expression of ATM in general was associated with increased survival (17.7 months, P = 0.001). CONCLUSIONS: Our analysis shows that both ATM expression and activated ATM are prognostic markers in PDAC with respect to standard clinicopathological parameters. These results suggest that ATM should be further explored as prognostic as well as predictive factor with respect to conventional chemotherapies and for putative synthetic lethal approaches.
Authors: Ronan Russell; Lukas Perkhofer; Stefan Liebau; Qiong Lin; André Lechel; Fenja M Feld; Elisabeth Hessmann; Jochen Gaedcke; Melanie Güthle; Martin Zenke; Daniel Hartmann; Guido von Figura; Stephanie E Weissinger; Karl-Lenhard Rudolph; Peter Möller; Jochen K Lennerz; Thomas Seufferlein; Martin Wagner; Alexander Kleger Journal: Nat Commun Date: 2015-07-29 Impact factor: 14.919
Authors: Liza C Villaruz; Helen Jones; Sanja Dacic; Shira Abberbock; Brenda F Kurland; Laura P Stabile; Jill M Siegfried; Thomas P Conrads; Neil R Smith; Mark J O'Connor; Andrew J Pierce; Christopher J Bakkenist Journal: Oncotarget Date: 2016-09-06
Authors: Gemma N Jones; Claire Rooney; Nicola Griffin; Martine Roudier; Lucy A Young; Antonio Garcia-Trinidad; Gareth D Hughes; Jeffrey R Whiteaker; Zena Wilson; Rajesh Odedra; Lei Zhao; Richard G Ivey; William J Howat; Elizabeth A Harrington; J Carl Barrett; Antonio Ramos-Montoya; Alan Lau; Amanda G Paulovich; Elaine B Cadogan; Andrew J Pierce Journal: Br J Cancer Date: 2018-11-02 Impact factor: 7.640
Authors: Charles R Dunlop; Yann Wallez; Timothy Isaac Johnson; Sandra Bernaldo de Quirós Fernández; Stephen T Durant; Elaine B Cadogan; Alan Lau; Frances M Richards; Duncan I Jodrell Journal: Br J Cancer Date: 2020-08-03 Impact factor: 7.640